Seit 24.10.1989 <strong>Deutsche</strong> <strong>Gesellschaft</strong> <strong>für</strong> Infektiologie e. V. Seit 1.2.1996 Mitglied der <strong>Deutsche</strong>n Krebsgesellschaft/AIO Seit 28.09.1998 Mitglied der <strong>Deutsche</strong>n <strong>Gesellschaft</strong> <strong>für</strong> Pneumologie 1991-1995 Mitglied des Beirates der Paul- Ehrlich-<strong>Gesellschaft</strong> <strong>für</strong> Chemotherapie e.V. Seit 29.11.2001 Mitglied der <strong>Deutsche</strong>n Sepsis- <strong>Gesellschaft</strong> Dresden, 20.02.11 Prof. Dr. med. G. <strong>Höffken</strong>
Publikationen seit 1999 <strong>Höffken</strong>, G., Pasold, R., Pflüger, K.H., Finke, J., Fauser, A.A., Szelenyi, H., Wagner, J. and the German Multicentre Study Group. An open, randomized , multicentre study comparing the use of low-dose ceftazidime or cefotaxime, both in combination with netilmicin, in febrile neutropenic patients. Journal of Antimicrobial Chemotherapy. 1999; 44: 367-376 Publication on Phase IV study <strong>Höffken</strong>, G., Bäthge, G., Kiderlen, A.F.. Pathogenese der Pneumocystis carinii Pneumonie. Pneumologie 1999; 53: 530-538 <strong>Höffken</strong>, G. Epidemiology of respiratory tract infection. European Respiratory Review 2000; 10: 149-155 <strong>Höffken</strong>, G. Is the use of narrow-spectrum antibiotics too narrow-minded in the treatment of severe infections? Clinical Microbiology and Infection 2000; 6 (Suppl. 2): 7-10 Landen, H, Möller, M, Tillotson, GS, Kubin, R, <strong>Höffken</strong>, G. Clinical experience in Germany of treating community-acquired respiratory infections with the new 8-Methoxyfluoroquinolone, Moxifloxacin. The Journal of International Medical Research 2001; 29: 51-60 Rubens, C., Ewert, R., Halank, M., Wensel, R., Orzechowski, H.-D., Schultheiss H.-P., <strong>Höffken</strong>, G. Big-Endothelin-1 and Endothelin-1 Plasma Levels are Correlated With the Severity of Primary Pulmonary Hypertension. Chest 2001; 120: 1562-1569 <strong>Höffken</strong>, G., Meyer, HP, Winter, J, Verhoef, L., CAP1 Study Group. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia. Respiratory Medicine 2001; 95: 553-564 Publication on Phase III study Jung, C., Buhl, M., Eichler, I., Borner, K., <strong>Höffken</strong>, G., Offermann, G. Orales versus intravenöses Ganciclovir in der präemptiven Therapie der Zytomegalievirusinfektion nach Nierentransplantation. Transplantationsmedizin 2001; 13: 37-43 Gillissen, A., <strong>Höffken</strong>, G. Early therapy with neuraminidase inhibitor oseltamivir maximizes its efficacy in influenza treatment. Med. Microbiol. Immunol. 2002; 191: 165-168 <strong>Höffken</strong>, G., Vogel, F., Huber, C. Wirksamkeit von Ceftazidim bei schweren nosokomialen Infektionen Chemotherapie-Journal 2002; 11: 207-213 Finch, R., Schürmann, D., Collins, O., Kubin, R., McGivern, J., Bobbaers, H., Izquierdo, J.L., Nikolaides, P., Ogundare, F., Raz, R., Zuck, P., <strong>Höffken</strong>, G. A randomised controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with communityacquired pneumonia requiring initial parenteral treatment. Antimicrobial Agents and Chemotherapy 2002; 46: 1746-1754 Publication on Phase III study <strong>Höffken</strong>, G., Gillissen, A.